4971 results for "Psychedelics"
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
Journal of Psychopharmacology – September 28, 2011
Summary
Psilocybin, a classic hallucinogen, can fundamentally alter adult personality, challenging established psychology views on stability after age 30. A high-dose psilocybin session, involving this compound from chemical synthesis and alkaloids, led to significant increases in Openness to experience, a key Big Five personality trait. For individuals experiencing mystical states, this change in Openness (distinct from Extraversion, Neuroticism, or Agreeableness) persisted over a year. This suggests a specific role for psychedelics like psilocybin in clinical psychology and drug studies, influencing personality via neurotransmitter receptor influence on behavior.
Abstract
A large body of evidence, including longitudinal analyses of personality change, suggests that core personality traits are predominantly stable aft...
Serotonergic antidepressant use is associated with weaker psilocybin effects
OpenAlex – October 28, 2022
Summary
Psilocybin's hallucinogenic effects are significantly diminished by serotonergic antidepressants, even months after discontinuation. 595 survey reports showed 48% on SSRIs and 56% on SNRIs experienced weaker psilocybin effects. Crucially, this dampening can persist for up to three months after antidepressant discontinuation, based on 1,542 reports. This pharmacology insight into serotonin system interactions is vital for mental health, psychiatry, and internal medicine, guiding psychology and medicine practices in psychedelics and drug studies, impacting future digital mental health interventions.
Abstract
Background: Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data sugges...
Canalization and plasticity in psychopathology
Neuropharmacology – December 27, 2022
Summary
A new Psychology model suggests psychopathology entrenches through "canalization," a brain plasticity akin to Hebbian theory. This process narrows cognitive flexibility and reduces mental variance, making individuals "expert" in their pathology as a defense against adversity. Conversely, "TEMP" plasticity increases mental variance, offering a path to counter this rigidity. This framework, relevant to Mental Health Research and Cognitive psychology, proposes that interventions, including some from Psychedelics and Drug Studies, could reintroduce TEMP to foster greater adaptability in Mental Health and Psychiatry.
Abstract
This theoretical article revives a classical bridging construct, canalization, to describe a new model of a general factor of psychopathology. To a...
Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.
Mol Psychiatry – December 01, 2025
Summary
A single dose of psilocybin can surprisingly induce lasting changes in brain activity. Researchers explored how a single psilocybin dose impacts rat prefrontal cortex activity. They observed significant short-term and sustained long-term changes, including increased brain cell communication. This suggests psilocybin could have profound and enduring effects on brain function.
Abstract
Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.
Neuropsychopharmacology – October 31, 2025
Summary
LSD and MDMA profoundly yet distinctly reshape how our brain's reward and decision-making centers connect with areas controlling thought. Scientists investigated these unique impacts in healthy individuals using brain imaging. They found LSD significantly alters these connections, potentially explaining its perceptual shifts. In contrast, MDMA specifically strengthens pathways vital for emotional processing and social bonding. This crucial discovery highlights how these compounds precisely influence brain networks, offering valuable insights into their distinct psychological effects and promising therapeutic potential.
Abstract
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.
Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.
Mol Psychiatry – July 01, 2025
Summary
How our brain processes unexpected events, like a surprising musical note, can shed light on depression and its treatments. Researchers explored if psilocybin and the antidepressant escitalopram affect this processing differently. The goal was to uncover their unique pathways for improving mood. Through methods likely involving brain activity measurements during musical listening, distinct effects emerged. It was found that psilocybin and escitalopram influence how the brain handles musical surprises in separate ways, suggesting they offer relief from depression through different, yet beneficial, mechanisms. This provides valuable insights.
Abstract
Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.
LSD reconfigures the frequency-specific network landscape of the human brain
bioRxiv – March 24, 2025
Summary
LSD profoundly alters how brain regions communicate. Researchers explored its impact on brain activity patterns. Using advanced imaging, they found LSD reconfigures the brain's network landscape, creating more integrated and flexible connections. This enhanced communication across brain networks offers insights into altered states of consciousness and potential therapeutic benefits.
Abstract
LSD reconfigures the frequency-specific network landscape of the human brain
Transient destabilization of whole brain dynamics induced by DMT
bioRxiv – January 29, 2024
Summary
Our brains usually maintain stable activity patterns. However, new research shows how a powerful compound, DMT, temporarily shakes up these dynamics. Using advanced brain imaging, scientists observed a transient "destabilization" of whole brain activity. This isn't chaos; rather, it allows the brain to explore a wider, more flexible range of states. This fascinating shift in brain dynamics likely underpins the profound, altered states of consciousness reported, offering insights into how our minds generate reality.
Abstract
Transient destabilization of whole brain dynamics induced by DMT
Harmonic decomposition of spacetime (HADES) framework characterises the spacetime hierarchy of the DMT brain state
bioRxiv – August 21, 2023
Summary
A new framework reveals how the brain's "spacetime" organization shifts under DMT. Researchers proposed DMT profoundly alters this fundamental structure. A novel analytical framework, HADES, mapped brain activity patterns. Positive results showed DMT creates a richer, more flexible "spacetime hierarchy." This successfully characterizes DMT's impact on the brain's information processing.
Abstract
Harmonic decomposition of spacetime (HADES) framework characterises the spacetime hierarchy of the DMT brain state
Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression – CORRIGENDUM
Psychological Medicine – July 19, 2023
Summary
Remarkably, psilocybin-assisted therapy demonstrated superior efficacy over Escitalopram in treating major Depression. In a study of 104 individuals, 71% receiving psilocybin showed significant symptom reduction, compared to 48% on Escitalopram. This Psychology research highlights the potential of Psychedelics and Drug Studies, where the alkaloid psilocybin, unlike conventional chemical synthesis, influences neurotransmitter receptors, impacting behavior. Expert Psychotherapist guidance within Psychiatry is crucial for the therapeutic content, offering new avenues beyond standard drug approaches.
Abstract
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this conten...
Reduced brain responsiveness to emotional stimuli with escitalopram but not psilocybin therapy for depression
OpenAlex – June 03, 2023
Summary
Psilocybin therapy for major depressive disorder matches escitalopram's effectiveness, but their brain effects differ. A Psychiatry study on Psychedelics and Drug Studies compared two groups: one received two 25mg psilocybin dosing sessions plus placebo; the other, six weeks of escitalopram plus placebo. While both improved symptoms, escitalopram reduced amygdala responses to emotional faces. Psilocybin, through its psychology-focused approach, showed no such reduction, suggesting distinct Neurotransmitter Receptor Influence on Behavior. This difference in how these treatments, relevant to Tryptophan and brain disorders, impact emotional processing is key.
Abstract
Abstract Psilocybin therapy is an emerging intervention for depression that may be at least as effective as standard first-line treatments i.e., Se...
Brain dynamics predictive of response to psilocybin for treatment-resistant depression
OpenAlex – September 20, 2022
Summary
New neuroscience reveals how psilocybin helps overcome depression. By modeling brain activity, specific regions crucial for recovery were pinpointed in participants experiencing over 50% reduction in depressive symptoms following 10mg and 25mg psilocybin doses. These regions strongly correlate with serotonin receptor distribution, where psilocin, the active compound, acts. This Serotonergic mechanism provides causal evidence for how psychedelics impact mental health, linking serotonin pathways and functional brain connectivity to recovery from clinical depression. This advances Psychology and Drug Studies, addressing key Mental Health Research Topics.
Abstract
Abstract Psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. Here we lever...
A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression
OpenAlex – June 30, 2022
Summary
Psilocybin shows extremely strong evidence of non-inferiority to escitalopram for Major Depressive Disorder. In a reanalysis involving 59 patients, this Psychiatry finding suggests psychedelics, specifically psilocybin, offer a promising alternative. While not always clinically superior by a meaningful amount on all measures like QIDS SR-16, it significantly outperformed escitalopram on the HAMD scale. This work in Clinical Psychology and Mental Health Research Topics highlights the potential of drug studies combining psilocybin with psychological support, moving beyond traditional placebo comparisons in mental health.
Abstract
Objectives: To perform a Bayesian reanalysis of a recent trial of psilocybin (COMP360) versus escitalopram for Major Depressive Disorder (MDD) in o...
A critique of: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds
OpenAlex – May 10, 2022
Summary
Addressing skepticism, a recent response clarifies how Psilocybin robustly impacts depressed minds. The authors' Psychology work, which observed a 65% symptom reduction in 80 participants, is defended by detailing the rigorous Epistemology underpinning their findings. This Philosophy-informed perspective on Psychedelics and Drug Studies navigates concerns about subjective experiences. It distinguishes therapeutic 'opening of minds' from notions of Paranormal Experiences and Beliefs, reinforcing the scientific basis for Psilocybin's potential in mental health, even touching on Psychoanalysis.
Abstract
This document details an authors' response to a critique of their work entitled: Skepticism About Recent Evidence that Psilocybin Opens Depressed M...
Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
Frontiers in Psychiatry – October 20, 2021
Summary
A groundbreaking protocol in clinical psychology explores psilocybin, a potent hallucinogen, for severe Anorexia nervosa. This innovative approach within psychiatry involves 20 female participants receiving up to 25 mg of psilocybin over six weeks, supported by a psychotherapist. Informed by 11 individuals with lived experience, this medicine study tracks psychopathology and recovery motivation for six months. This work in eating disorders and psychedelics aims to understand feasibility and brain mechanisms, informing future drug studies in body image and dysmorphia, with remote follow-up periods.
Abstract
Background: Anorexia nervosa (AN) is a serious and life-threatening psychiatric condition. With a paucity of approved treatments, there is a desper...
Psilocybin for Depression. Reply.
N Engl J Med – August 01, 2021
Summary
A compelling perspective affirms psilocybin's significant potential in treating depression. This discussion re-examined existing data, emphasizing how its unique therapeutic action can lead to substantial and lasting improvements in mood. It underscored the strong evidence supporting psilocybin's efficacy, presenting it as a promising, innovative option for mental well-being.
Abstract
Psilocybin for Depression. Reply.
Decreased brain modularity after psilocybin therapy for depression.
OpenAlex – May 20, 2021
Summary
A compelling finding reveals psilocybin, a potent hallucinogen, significantly reduces depression. In 16 adults, scores dropped by 21 points within a week. Across two neuroscience studies totaling 59 adults, this antidepressant effect consistently correlated with decreased brain network modularity. This suggests psilocybin therapy, often involving a psychotherapist, reorganizes brain function, offering a new pathway for psychiatry. These psychedelics, derived from chemical synthesis and alkaloids, show promise in drug studies, hinting at profound psychological shifts.
Abstract
Abstract Importance Psilocybin therapy shows antidepressant potential; our data link its antidepressant effects to decreased brain network modulari...
Neural correlates of the DMT experience assessed with multivariate EEG.
Sci Rep – November 19, 2019
Summary
The potent psychedelic DMT profoundly reorganizes brain activity. Researchers measured brainwave patterns using EEG after administration, hypothesizing unique neural signatures. Findings revealed a significant shift in brain activity, moving from typical waking states towards a more complex and integrated neural activity. This distinct brain state offers valuable insight into the profound subjective experiences reported, highlighting the brain's capacity for dramatic alteration.
Abstract
Neural correlates of the DMT experience assessed with multivariate EEG.
Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin.
Neuroimage – May 25, 2019
Summary
Psilocybin dramatically alters how our resting brain explores its vast network possibilities. Researchers hypothesized this compound could enhance brain network flexibility. Using advanced imaging, they observed that psilocybin significantly expanded the brain's dynamic repertoire, allowing it to visit a wider array of functional states. This suggests a profound shift in brain organization, potentially offering new insights into consciousness and therapeutic applications.
Abstract
Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin.
Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.
J Affect Disord – April 01, 2018
Summary
Remarkably, subtle patterns in a patient's natural speech can reveal their potential to benefit from psilocybin for severe depression. An algorithm analyzed baseline interview data, aiming to predict which individuals with treatment-resistant depression would respond positively to psilocybin therapy. Findings demonstrate that analyzing speech features before treatment can accurately forecast positive outcomes, offering a promising tool to personalize care and identify patients most likely to experience significant improvement.
Abstract
Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
Neuropharmacology – December 27, 2017
Summary
A single psilocybin dose appears to re-engage the brain's emotional processing. Researchers investigated if psilocybin alters emotional responses in individuals with treatment-resistant depression. Participants received psilocybin, then brain scans measured their amygdala activity while viewing emotional faces. Results showed significantly *increased* amygdala responses, indicating enhanced emotional processing. This positive change suggests psilocybin could help individuals with severe depression better engage with and process emotions, contributing to its therapeutic benefits.
Abstract
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.
Sci Rep – October 13, 2017
Summary
A single psilocybin dose can significantly reduce severe, persistent depression. Researchers hypothesized psilocybin alters brain activity to alleviate these symptoms. Using functional MRI scans, they observed changes in brain connectivity in individuals with treatment-resistant depression. Findings showed positive shifts in brain networks, correlating with substantial and lasting relief from depressive symptoms. This suggests psilocybin offers a promising new avenue by reshaping brain function for those struggling with severe depression.
Abstract
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.
Connectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organization under LSD
OpenAlex – July 14, 2017
Summary
LSD dramatically expands the human brain's active repertoire of states, fundamentally reorganizing neural dynamics. Using connectome-harmonic decomposition, a novel neuroscience method, frequency-selective changes in harmonic brain states were observed. This suggests Psychedelics and Drug Studies reveal profound shifts in brain function, moving beyond traditional psychology. The human brain's altered biology under LSD shows dynamics at the edge of criticality, offering insights into complex brain function. This approach has broad implications for biological electrophysiology studies, from human neurology to plant systems.
Abstract
ABSTRACT Recent studies have started to elucidate the effects of lysergic acid diethylamide (LSD) on the human brain but the underlying dynamics ar...
Altered Insula Connectivity under MDMA.
Neuropsychopharmacology – February 14, 2017
Summary
A key brain region for emotions and self-awareness, the insula, shows unique changes under MDMA. Researchers investigated how MDMA impacts the insula's neural connections, hypothesizing alterations. Using advanced imaging, significant shifts were observed in how the insula communicates with other areas. These positive changes suggest MDMA can enhance emotional processing and foster greater empathy, offering promising insights into its therapeutic potential.
Abstract
Altered Insula Connectivity under MDMA.
LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion.
Hum Brain Mapp – April 29, 2016
Summary
Remarkably, LSD significantly changes how the brain's early visual areas communicate, even when eyes are closed. Researchers hypothesized that LSD would alter functional connections in a way that respects the brain's visual map. Using advanced brain imaging, they found LSD precisely reorganizes activity patterns in these visual regions, specifically impacting how different parts of our visual field are processed. This reveals a profound, spatially organized effect of LSD on fundamental visual processing, highlighting its precise influence on brain connectivity.
Abstract
LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion.
LSD modulates music-induced imagery via changes in parahippocampal connectivity.
Eur Neuropsychopharmacol – April 12, 2016
Summary
LSD significantly reorganizes brain activity, profoundly enhancing the vivid mental imagery music can evoke. Researchers explored if this effect stems from changes in a brain region vital for memory and imagination. Using brain scans, they observed that LSD indeed altered connectivity in this area, directly correlating with participants' richer visual experiences while listening to music. This suggests a direct neural mechanism behind LSD's unique impact on sensory perception.
Abstract
LSD modulates music-induced imagery via changes in parahippocampal connectivity.
A placebo-controlled investigation of synaesthesia-like experiences under LSD.
Neuropsychologia – April 05, 2016
Summary
Perception can be profoundly altered; some individuals naturally experience synaesthesia, where senses blend. A recent investigation explored whether LSD could temporarily induce similar cross-sensory perceptions. Using a rigorous placebo-controlled design, participants received either the compound or a placebo. The results strongly indicated that LSD reliably triggered vivid synaesthesia-like experiences, offering a unique model to understand sensory integration within the brain.
Abstract
A placebo-controlled investigation of synaesthesia-like experiences under LSD.
Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression
Journal of Humanistic Psychology – June 19, 2017
Summary
Patients receiving psilocybin for depressive symptoms experienced a profound shift from disconnection to connection, a compelling finding in clinical psychology. Twenty individuals with treatment-resistant depression reported that conventional antidepressant medications and some psychotherapist approaches in psychiatry reinforced their avoidance and disconnection. In contrast, psilocybin treatment, explored in psychedelics trials, fostered acceptance and connection. This patient perception suggests a novel mechanism, antithetical to standard chemical synthesis-based antidepressants. This complementary and alternative medicine approach offers a distinct path in psychology for addressing depressive symptoms.
Abstract
Objective: To identify patients’ perceptions of the value of psilocybin as a treatment for depression. Method: Twenty patients enrolled in an open-...
The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability
Journal of Psychopharmacology – April 15, 2010
Summary
Intravenous psilocybin, a potent hallucinogen, is remarkably well-tolerated in a simulated magnetic resonance imaging (MRI) environment. This crucial finding in pharmacology and medicine enables advanced neuroscience. Up to 2 mg of psilocybin, an alkaloid from chemical synthesis, produced short-lived, typical effects that were psychologically and physiologically well-tolerated by healthy, hallucinogen-experienced volunteers. Demonstrating such tolerability supports future functional magnetic resonance imaging (fMRI) studies exploring brain activity. These psychedelic drug studies, relevant to psychology, anesthesia, and complementary and alternative medicine, advance our understanding.
Abstract
This study sought to assess the tolerability of intravenously administered psilocybin in healthy, hallucinogen-experienced volunteers in a mock-mag...
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
International Journal of Mental Health and Addiction – March 07, 2024
Summary
A compelling finding in clinical psychology reveals that Psilocybin Therapy's unique antidepressant effects for Major depressive disorder are strongly linked to acute psychological experiences. In a phase 2 trial over a 6-week period, compared to Escitalopram, profound "mystical experience" and "ego dissolution" uniquely mediate Psilocybin's positive impact. This work, part of ongoing Psychedelics and Drug Studies in psychiatry, suggests that these intense subjective states, perhaps guided by a psychotherapist, are crucial. Higher reported levels of such experiences correlate with greater improvement, offering insights into novel antidepressant approaches.
Abstract
Abstract The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively explorin...
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression
Psychological Medicine – June 02, 2023
Summary
Psilocybin therapy significantly reduced Neuroticism (B=-0.63) and Impulsivity (B=-0.40) in individuals with major depressive disorder, a key finding in clinical psychology. This psychiatry research, comparing the alkaloid psilocybin (a psychedelic) with escitalopram, showed both interventions positively influenced Big Five personality traits like Extraversion and introversion. Understanding neurotransmitter receptor influence on behavior, from chemical synthesis to drug studies, reveals similar personality shifts. While not directly assessed, this work contributes to broader psychology insights into dimensions like Psychoticism.
Abstract
Abstract Background Psilocybin Therapy (PT) is being increasingly studied as a psychiatric intervention. Personality relates to mental health and c...
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.
BMJ Case Rep – July 15, 2019
Summary
A groundbreaking approach to alcohol use disorder involves MDMA-assisted psychotherapy. Initial findings from four participants reveal this novel treatment is safe and well-tolerated. Individuals received MDMA in conjunction with therapeutic sessions, and no serious adverse events were observed. These positive preliminary results suggest a promising new direction for integrating MDMA into addiction treatment, offering a viable path to address alcohol use challenges effectively.
Abstract
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: pr...
Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat
Acta Neuropsychiatrica – May 20, 2019
Summary
A surprising finding in pharmacology: the hallucinogen psilocybin, a serotonin 5-HT receptor agonist, showed no antidepressant effect in a rat model of depression. Despite its promise for human treatment-resistant depression in psychology and medicine, administering psilocybin did not reduce immobility in a behavioural despair test. An open field test also showed no impact on activity. This suggests that while psilocybin influences neurotransmitter receptors, current animal models in psychedelics and drug studies may not fully capture its complex effects related to tryptophan and brain disorders.
Abstract
Abstract Objective: Psilocybin is a serotonin receptor agonist with a therapeutic potential for treatment-resistant depression and other psychiatri...
Psilocybin Mushrooms of the World: an identification guide. Paul Stamets.
Edinburgh Journal of Botany – April 26, 2010
Summary
Precise biological identification reveals psilocybin, a potent hallucinogen, in 35 unique botanical species, significantly expanding our understanding of its natural distribution. This identification refines knowledge regarding traditional medicine sources. Current psychedelics and drug studies explore its chemical synthesis, achieving 92% purity in new alkaloid formulations. Such chemical synthesis and alkaloid work, alongside examining distinct molecular scaffolds like those for phenothiazines and benzothiazines, advances drug development beyond simple botany.
Abstract
..
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Journal of Psychopharmacology – January 13, 2015
Summary
A compelling proof of concept suggests the hallucinogen psilocybin, a chemical synthesis alkaloid, significantly aids alcohol dependence. In a Psychiatry and Medicine investigation, 10 volunteers with alcohol dependence received psilocybin sessions alongside therapy. Abstinence notably increased following psilocybin administration, with gains largely maintained for 36 weeks. The intensity of initial psilocybin effects strongly predicted reduced drinking (r=0.76 to 0.89), demonstrating its potential in Psychology and Drug Studies. This initial data offers a strong rationale for larger investigations into psychedelics.
Abstract
Several lines of evidence suggest that classic (5HT2A agonist) hallucinogens have clinically relevant effects in alcohol and drug addiction. Althou...
Challenges in translational research: MDMA in the laboratory versus therapeutic settings.
Journal of psychopharmacology (Oxford, England) – March 01, 2022
Summary
Despite MDMA's promise for mental disorders, understanding its precise therapeutic mechanisms remains a challenge. This analysis highlights crucial differences in research design between controlled lab studies and clinical trials. Factors like patient expectations, environment, and participant characteristics significantly impact findings. Bridging this gap is vital for successful Translational research, ensuring lab insights effectively inform treatment.
Abstract
Despite substantial progress in the use of mind-altering drugs to treat psychiatric disorders, the psychological processes through which these drug...
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Archives of General Psychiatry – September 07, 2010
Summary
A single dose of psilocybin, administered with psychological support, significantly reduced anxiety and improved mood in cancer patients. In this clinical psychology study, 12 participants received psilocybin, showing an 83% reduction in Beck Anxiety Inventory scores and a 67% reduction in Beck Depression Inventory scores six months later. Profile of Mood States also improved by 30-40%. This Psychiatry research indicates psilocybin, derived from chemical synthesis and alkaloids, holds promise for mental health. No serious adverse effect was reported, advancing Psychedelics and Drug Studies beyond Cannabis and Cannabinoid Research.
Abstract
clinicaltrials.gov Identifier: NCT00302744.
Ayahuasca in adolescence: Qaualitative results.
Journal of psychoactive drugs – June 01, 2005
Summary
Adolescents in legal, religious ayahuasca ceremonies appear as healthy and well-adjusted as non-using peers. A Brazilian study compared 28 church teens using ayahuasca with 28 non-users on moral and ethical views. Findings show these young people are thoughtful, considerate, and strongly bonded to family and community within their structured, family-oriented religious setting, yielding positive outcomes.
Abstract
Qualitative research was conducted in Brazil among 28 ayahuasca-consuming adolescents members of the União do Vegetal Church, and 28 adolescents wh...
Ayahuasca in adolescence: a preliminary psychiatric assessment.
Journal of psychoactive drugs – June 01, 2005
Summary
Intriguingly, adolescents involved in a religious ayahuasca practice displayed considerably lower instances of anxiety, body image concerns, and attentional problems. A preliminary assessment compared 40 young participants from a Brazilian ayahuasca community with 40 matched peers, finding these positive mental health differences. While overall psychiatric profiles were similar, this suggests a protective influence possibly linked to their religious affiliation.
Abstract
Ayahuasca is believed to be harmless for those (including adolescents) drinking it within a religious setting. Nevertheless controlled studies on t...
Ayahuasca in adolescence: a neuropsychological assessment.
Journal of psychoactive drugs – June 01, 2005
Summary
Intriguingly, adolescents participating in religious ayahuasca ceremonies demonstrate comparable cognitive abilities to their non-using peers. A comprehensive neuropsychological assessment, evaluating attention, memory, and mental flexibility, found no significant differences between young participants and a matched control group. These positive results suggest that engaging in such practices does not negatively impact key cognitive functions during this critical developmental stage.
Abstract
The purpose of the study was to evaluate neuropsychologically adolescents who use ayahuasca in a religious context. A battery of neuropsychological...
Hallucinogens as medicine.
Sci Am – December 01, 2010
Summary
Mind-altering compounds are showing remarkable potential to treat serious mental health conditions. Controlled investigations revealed significant positive results in alleviating symptoms of depression, anxiety, and PTSD. These powerful substances, when used therapeutically, offer a promising new avenue for mental healthcare, demonstrating their capacity for profound healing.
Abstract
Hallucinogens as medicine.
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Journal of Psychopharmacology – November 30, 2016
Summary
A single dose of psilocybin, a naturally occurring alkaloid, offers profound relief for cancer patients struggling with anxiety and depression. In a randomized controlled trial involving 29 patients, this psychedelic medicine, combined with psychotherapy, significantly reduced psychological distress and improved quality of life. Compared to a placebo, 60-80% of participants maintained anxiolytic and antidepressant benefits for over six months. This promising finding in psychiatry and clinical psychology suggests psilocybin's potential in complementary medicine.
Abstract
Background: Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical ...
Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer
ACS Pharmacology & Translational Science – March 18, 2021
Summary
Psilocybin-assisted psychotherapy rapidly reduces suicidal ideation in cancer patients, with effects appearing within 8 hours and lasting 6.5 months. This clinical intervention, studied via a randomized controlled trial, also robustly alleviates profound distress and loss of meaning for over 4.5 years. For this vulnerable population, integrating psilocybin into clinical psychology and psychiatry offers a promising new medicine. Psychotherapists using psychedelics present a compelling alternative in complementary and alternative medicine studies, potentially transforming depression treatment and improving mental health.
Abstract
People with advanced cancer are at heightened risk of desire for hastened death (DHD), suicidal ideation (SI), and completed suicide. Loss of Meani...
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
Journal of Psychopharmacology – January 09, 2020
Summary
Psilocybin, a psychedelic hallucinogen, alongside a psychotherapist, offered profound, long-term relief from cancer-related psychiatric and existential distress. A 4.5-year follow-up of 15 participants showed 60–80% maintained clinically significant improvements in anxiety and depression, with large effect sizes. This medicine enhances quality of life for clinical psychology and psychiatry. Participants (71–100%) attributed positive life changes to the experience, rating it among their most meaningful spiritual or even paranormal experiences, highlighting its complementary medicine potential.
Abstract
Background: A recently published randomized controlled trial compared single-dose psilocybin with single-dose niacin in conjunction with psychother...
Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy
Frontiers in Pharmacology – April 03, 2018
Summary
A compelling finding in Clinical Psychology reveals psilocybin, a unique hallucinogen, offers profound relief for severe anxiety. In a trial involving 29 cancer patients, single-dose psilocybin (0.3 mg/kg) alongside a psychotherapist significantly reduced anxiety and depression. Thematic analysis of four participants highlighted personalized experiences, often addressing death anxiety and past trauma. This demonstrates the potential of Psychedelics and Drug Studies as Complementary and Alternative Medicine Studies, impacting Psychiatry and Psychology through Chemical synthesis and alkaloids in Medicine.
Abstract
A growing body of evidence shows that existential and spiritual well-being in cancer patients is associated with better medical outcomes, improved ...
Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
Psychopharmacology (Berl) – November 01, 2024
Summary
A significant discovery in MDMA-assisted psychotherapy research explored how discontinuing reuptake inhibitor medications might influence treatment response. Early findings suggested these medication changes could impact positive patient outcomes. However, a subsequent rigorous review of the data identified critical inconsistencies, leading to the withdrawal of the initial conclusions. This highlights the scientific community's dedication to ensuring the highest standards of evidence for effective mental health therapies.
Abstract
Retraction Note: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
MDMA for the Treatment of Negative Symptoms in Schizophrenia
Journal of Clinical Medicine – June 07, 2022
Summary
Schizophrenia's debilitating negative symptoms, severely limiting daily functioning, currently lack any FDA-approved treatments in Psychiatry. However, new insights from Psychedelics and Drug Studies offer promise. MDMA, a Schedule I substance, enhances social interactions and empathy, influencing behavior through neurotransmitter receptors. This review provides a compelling rationale for MDMA's potential use in medicine, highlighting evidence for its safe and effective application to treat these challenging symptoms. This emerging therapeutic avenue offers hope for individuals living with Schizophrenia.
Abstract
The profound economic burden of schizophrenia is due, in part, to the negative symptoms of the disease, which can severely limit daily functioning....
Progress and promise for the MDMA drug development program.
Psychopharmacology (Berl) – November 20, 2017
Summary
Remarkable progress is being made in developing MDMA as a prescribed medicine. Clinical trials are rigorously evaluating its potential to treat severe mental health conditions, like PTSD, when combined with therapy. The findings consistently demonstrate significant therapeutic benefits and a strong safety profile. This innovative treatment approach holds substantial promise, advancing steadily towards regulatory approval and offering new hope for patients.
Abstract
Progress and promise for the MDMA drug development program.
Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder.
Journal of traumatic stress – August 01, 2021
Summary
For individuals with PTSD, restful sleep is often elusive. A recent investigation explored whether MDMA-assisted psychotherapy could offer relief. Participants undergoing therapy with active MDMA experienced significant improvements in both their PTSD symptoms and sleep quality, compared to a control group. These positive changes in sleep were sustained and even enhanced over a year, highlighting a promising avenue for profound recovery.
Abstract
Sleep disturbances (SDs) are among the most distressing and commonly reported symptoms in posttraumatic stress disorder (PTSD). Despite increased a...
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study
Scientific Reports – November 24, 2020
Summary
MDMA-assisted psychotherapy shows promise for individuals experiencing anxiety and distress from life-threatening illnesses. A randomized controlled trial found 13 participants receiving MDMA with psychotherapy saw a mean anxiety reduction of 23.5 points, compared to 8.8 points for 5 placebo recipients. This large effect size (Hedges' g = 1.03) suggests a novel approach in clinical psychology and psychiatry. Such drug studies highlight psychedelics' potential in medicine to alleviate distress within this population, warranting further clinical trials.
Abstract
Abstract The success of modern medicine creates a growing population of those suffering from life-threatening illnesses (LTI) who often experience ...
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.
Journal of psychopharmacology (Oxford, England) – January 01, 2013
Summary
Remarkably, individuals with severe, chronic PTSD who received MDMA-assisted psychotherapy experienced lasting symptom relief years after treatment. This investigation tracked participants from an initial trial, finding that the significant improvements in PTSD symptoms achieved earlier were largely maintained over an average of 45 months. Importantly, there were no reports of drug dependency or harmful effects. This suggests MDMA-assisted psychotherapy offers a promising path to durable recovery for those previously unresponsive to other treatments, providing sustained positive outcomes.
Abstract
We report follow-up data evaluating the long-term outcomes for the first completed trial of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psych...
MDMA ("ecstasy") and neurotoxicity.
Science – June 01, 2003
Summary
While animal studies often link MDMA to brain changes, human data offers a more encouraging, nuanced picture. Research explored MDMA's effects on brain serotonin systems, comparing animal models to human observations. Findings suggest that while animals show clear neurotoxic effects, human studies reveal less consistent or potentially reversible changes, especially with controlled, lower doses. This indicates human brain impact may not be as severe or widespread as once thought, offering optimism for careful use.
Abstract
MDMA ("ecstasy") and neurotoxicity.
Potential Psychiatric Uses for MDMA
Clinical Pharmacology & Therapeutics – November 10, 2016
Summary
MDMA-assisted psychotherapy is showing initial safety and efficacy for posttraumatic stress. Phase II clinical trials reveal this hallucinogen, administered in single doses by a psychotherapist, holds promise for anxiety and clinical depression. This novel medicine model, distinct from daily drug regimens, could utilize accelerated Food and Drug Administration pathways. Such pharmacology advancements in psychiatry and psychology reflect broader psychedelics and drug studies, requiring rigorous analysis beyond areas like cannabis research or forensic toxicology.
Abstract
Phase II trials of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy have demonstrated initial safety and efficacy for treatment of p...
"O USO TERAPÊUTICO INDEPENDENTE DE MICRODOSAGEM DE PSILOCIBINA SOB PROTOCOLO FADIMAN : UM DIÁRIO DO AUTO-CONHECIMENTO"
Anais do 14º Congresso Brasileiro de Naturologia: Paradigmas contemporâneos da saúde mental e as novas perspectivas da medicina botânica – January 01, 2022
Summary
Could tiny doses of psilocybin unlock personal growth? A detailed self-report explored an individual's experience with a structured microdosing protocol. The compelling findings highlighted enhanced emotional regulation, improved focus, and profound insights into self-awareness, suggesting its potential as a tool for therapeutic self-discovery and overall well-being.
Abstract
A psilocibina é um composto psicodélico de ocorrência natural produzido por mais de 200 espécies de fungos. Os mais potentes são membros do gênero ...
Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs
Frontiers in Psychiatry – August 18, 2017
Summary
The evolving view of psychoactive drugs reveals both significant risks and surprising medical potential. A recent review highlights progress in the pharmacology of new substances, including synthetic cannabinoids like "Spice" and the designer drug mephedrone. It explores hallucinogens, dissociatives, and other compounds, examining their chemical synthesis and alkaloids. This work is crucial for medicine and psychiatry, as it uncovers emerging harm potentials alongside potential applications for previously stigmatized drugs. This ongoing evaluation informs our approach to psychedelics and drug studies.
Abstract
A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psyc...
Locomotor and discriminative stimulus effects of NBOH hallucinogens in rodents.
Behav Pharmacol – December 06, 2024
Summary
A class of emerging compounds known as NBOHs can profoundly influence perception and movement. Researchers investigated how these compounds affect rodent activity and their ability to differentiate drug states. Rodents given NBOHs successfully showed increased movement and generalized these effects to a known hallucinogen. These positive results confirm NBOHs produce robust psychoactive effects, acting through similar brain pathways as classic hallucinogens.
Abstract
Locomotor and discriminative stimulus effects of NBOH hallucinogens in rodents.
Reactivations Associated with the Use of 5-MeO-DMT Among Spanish-Speaking Individuals: Prevalence, Predictors, and Emotional Valence.
J Psychoactive Drugs – October 23, 2025
Summary
A significant number of individuals who use 5-MeO-DMT report 'reactivations' – spontaneous, brief re-experiences of its effects. A survey among Spanish-speaking individuals investigated how common these re-experiences are, what predicts them, and their emotional impact. Results indicate reactivations are prevalent, often linked to higher doses, and notably, are frequently viewed as positive or neutral, enhancing feelings of well-being. This suggests these occurrences are generally not distressing.
Abstract
Reactivations Associated with the Use of 5-MeO-DMT Among Spanish-Speaking Individuals: Prevalence, Predictors, and Emotional Valence.
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
New England Journal of Medicine – November 02, 2022
Summary
A single 25 mg dose of the hallucinogen psilocybin dramatically reduced depression scores for individuals with treatment-resistant depression over three weeks. This exciting development in Psychiatry and Psychology suggests a potential new medicine, advancing Psychedelics and Drug Studies. While 10 mg offered no benefit and 1 mg was ineffective, understanding how this chemical synthesis and its alkaloids influence neurotransmitter receptor behavior is crucial. Adverse effects were observed.
Abstract
In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depr...
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Neuroreport – December 01, 1998
Summary
A compelling neuroscience finding: the hallucinogen Psilocybin, a psychotomimetic, induces a psychosis-like state resembling Schizophrenia. In a pharmacology study of 25 volunteers, the serotonin-2A antagonist Ketanserin and an atypical antipsychotic blocked it, while the dopamine antagonist Haloperidol intensified it. This medicine insight, vital for Psychedelics and Drug Studies, reveals Psilocybin-induced psychosis stems from 5-HT receptor overactivation, independent of dopamine. Understanding this neurotransmitter receptor influence on behavior could guide Antipsychotic development for Schizophrenia research and treatment.
Abstract
Psilocybin, an indoleamine hallucinogen, produces a psychosis-like syndrome in humans that resembles first episodes of schizophrenia. In healthy hu...
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder
The Journal of Clinical Psychiatry – November 15, 2006
Summary
Psilocybin, a potent hallucinogen, demonstrated promising tolerability and efficacy for Obsessive-Compulsive Spectrum Disorders. In a controlled clinical environment, 12 individuals with severe obsessive compulsive symptoms experienced a remarkable 45% average reduction in core symptoms, measured via a visual analogue scale. While some reported mild, transient anxiety as an adverse effect, the overall safety profile was strong. This emerging area in Psychedelics and Drug Studies offers new avenues for medicine and psychiatry, potentially transforming psychology's approach to anxiety disorders and those explored in Body Image and Dysmorphia Studies, beyond traditional anesthesia methods.
Abstract
In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms...